ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,013.13
      -1.71%
      US Tech 100
      21,039.16
      -2.09%
      Dow Jones
      43,428.02
      -1.69%
      Brent Oil
      74.105
      0.23%
      Bitcoin
      96,259.67
      -0.32%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Arcturus Therapeutics Holdings Inc (ARCT) Quote

      Arcturus Therapeutics Holdings Inc

      Arcturus Therapeutics Holdings Inc (ARCT)

      NASDAQ
      17.77
      0.85
      (5.02%)
      Closed February 23 4:00PM
      Delayed by 15 minutes
      17.75
      -0.02
      (-0.11%)
      After Hours: 7:10PM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      17.75
      Bid
      17.52
      Ask
      18.50
      Volume
      436,047
      16.63 Day's Range 17.86
      14.30 52 Week Range 45.00
      Market Cap
      480.801M
      Previous Close
      16.92
      Open
      17.24
      Last Trade
      10
      @
      17.75
      Last Trade Time
      Financial Volume
      $ 7,485,516
      VWAP
      17.1668
      Average Volume (3m)
      403,172
      Shares Outstanding
      27,087,359
      Dividend Yield
      -
      PE Ratio
      -16.19
      Earnings Per Share (EPS)
      -1.1
      Revenue
      166.8M
      Net Profit
      -29.73M

      About Arcturus Therapeutics Holdings Inc

      Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of... Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      arcturusrx.com
      Headquarters
      San Diego, California, USA
      Founded
      -
      Arcturus Therapeutics Holdings Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ARCT. The last closing price for Arcturus Therapeutics was $16.92. Over the last year, Arcturus Therapeutics shares have traded in a share price range of $ 14.30 to $ 45.00.

      Arcturus Therapeutics currently has 27,087,359 shares outstanding. The market capitalization of Arcturus Therapeutics is $458.32 million. Arcturus Therapeutics has a price to earnings ratio (PE ratio) of -16.19.

      Ask ADVFN Intelligence (AI)

      ARCT Latest News

      More News

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      December 18 2024
      ARCT (5.02%)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      11.257.5757575757616.519.1716.555574217.62769955CS
      40.352.0114942528717.419.1715.3443605616.91211154CS
      120.080.45274476513917.6721.2614.340317217.17101821CS
      26-3.68-17.172188520821.4325.8814.339282418.64546189CS
      52-17.34-49.415787973835.094514.346834924.99067652CS
      156-4.23-19.244767970921.984511.748611423.24791913CS
      2603.0220.502376103214.73129.718.5162070437.72633273CS

      ARCT - Frequently Asked Questions (FAQ)

      What is the current Arcturus Therapeutics share price?
      The current share price of Arcturus Therapeutics is $ 17.75
      How many Arcturus Therapeutics shares are in issue?
      Arcturus Therapeutics has 27,087,359 shares in issue
      What is the market cap of Arcturus Therapeutics?
      The market capitalisation of Arcturus Therapeutics is USD 458.32M
      What is the 1 year trading range for Arcturus Therapeutics share price?
      Arcturus Therapeutics has traded in the range of $ 14.30 to $ 45.00 during the past year
      What is the PE ratio of Arcturus Therapeutics?
      The price to earnings ratio of Arcturus Therapeutics is -16.19
      What is the cash to sales ratio of Arcturus Therapeutics?
      The cash to sales ratio of Arcturus Therapeutics is 2.89
      What is the reporting currency for Arcturus Therapeutics?
      Arcturus Therapeutics reports financial results in USD
      What is the latest annual turnover for Arcturus Therapeutics?
      The latest annual turnover of Arcturus Therapeutics is USD 166.8M
      What is the latest annual profit for Arcturus Therapeutics?
      The latest annual profit of Arcturus Therapeutics is USD -29.73M
      What is the registered address of Arcturus Therapeutics?
      The registered address for Arcturus Therapeutics is 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO, CALIFORNIA, 92121
      What is the Arcturus Therapeutics website address?
      The website address for Arcturus Therapeutics is arcturusrx.com
      Which industry sector does Arcturus Therapeutics operate in?
      Arcturus Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      MLGOMicroAlgo Inc
      $ 6.3767
      (454.50%)
      		531.54M
      BOXLBoxlight Corporation
      $ 3.1099
      (51.70%)
      		1.84M
      GDEVGDEV Inc
      $ 20.90
      (46.56%)
      		264.44k
      IVVDInvivyd Inc
      $ 1.7501
      (44.64%)
      		37.75M
      UPCUniverse Pharmaceuticals Inc
      $ 0.2003
      (40.56%)
      		420.21M
      DOYUDouYu International Holdings Ltd
      $ 7.19
      (-55.31%)
      		1.28M
      MNDRMobile health Network Solutions
      $ 0.5048
      (-46.29%)
      		18.61M
      BLUEbluebird bio Inc
      $ 4.09
      (-41.90%)
      		5.44M
      FLDFold Holdings Inc
      $ 6.95
      (-37.39%)
      		488.54k
      GCLGCL Global Holdings Ltd
      $ 3.83
      (-31.48%)
      		635.26k
      MLGOMicroAlgo Inc
      $ 6.3767
      (454.50%)
      		531.54M
      UPCUniverse Pharmaceuticals Inc
      $ 0.2003
      (40.56%)
      		420.21M
      ADTXAditxt Inc
      $ 0.0922
      (-22.39%)
      		278.25M
      NVDANVIDIA Corporation
      $ 134.43
      (-4.05%)
      		228.14M
      HOLOMicroCloud Hologram Inc
      $ 1.565
      (31.51%)
      		190.81M

      ARCT Discussion

      View Posts
      Monksdream Monksdream 5 months ago
      ARCT a buy again
      👍️0
      Monksdream Monksdream 6 months ago
      That awful Cathie Wood has been a recent buyer
      👍️0
      Monksdream Monksdream 7 months ago
      ARCT 10Q due AUGUST5
      👍️0
      Monksdream Monksdream 12 months ago
      ARCT 10Q due March 7
      👍️0
      Monksdream Monksdream 1 year ago
      ARCT new 52 week high
      👍️0
      Monksdream Monksdream 2 years ago
      Arcturus Therapeutics (ARCT)
      icon-fall
      19%
      Shares of Arcturus Therapeutics traded down ~19% on Tuesday after the company announced4 lower-than-expected revenue and earnings for the second quarter. According to management, revenue declined in response to the termination of two agreements, one with Vinbiocare and another with the Israeli Ministry of Health. Arcturus Therapeutics develops mRNA-based vaccines and therapeutics for the treatment of infectious and rare genetic diseases.
      👍️0
      Monksdream Monksdream 2 years ago
      Arcturus Therapeutics Holdings Inc NASDAQ: ARCT

      GoSymbol lookup
      Health Care : Biotechnology | Small Cap GrowthCompany profile
      Arcturus Therapeutics Holdings Inc. is a global late-stage clinical messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform







      and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.
      Arcturus Therapeutics (ARCT)
      icon-rise-1
      15%
      Shares of Arcturus Therapeutics traded up ~15% on Friday after the company’s vaccine, ARCT-154, demonstrated6 an improvement in immunogenicity—43% more neutralizing antibodies at a lower dose than Comirnaty®. Arcturus Therapeutics develops mRNA-based vaccines and therapeutics for the treatment of infectious and rare genetic diseases.

      Arcturus Therapeutics (ARCT)
      icon-rise-1
      15%
      Shares of Arcturus Therapeutics traded up ~15% on Friday after the company’s vaccine, ARCT-154, demonstrated6 an improvement in immunogenicity—43% more neutralizing antibodies at a lower dose than Comirnaty®. Arcturus Therapeutics develops mRNA-based vaccines and therapeutics for the treatment of infectious and rare genetic diseases.
      Arcturus Therapeutics (ARCT)
      icon-rise-1
      15%
      Shares of Arcturus Therapeutics traded up ~15% on Friday after the company’s vaccine, ARCT-154, demonstrated6 an improvement in immunogenicity—43% more neutralizing antibodies at a lower dose than Comirnaty®. Arcturus Therapeutics develops mRNA-based vaccines and therapeutics for the treatment of infectious and rare genetic diseases.
      👍️0
      IOUBLOKE1 IOUBLOKE1 3 years ago
      Silence is golden ARC
      👍️0
      IOUBLOKE1 IOUBLOKE1 3 years ago
      Wow big after hours green buy
      👍️0
      IOUBLOKE1 IOUBLOKE1 3 years ago
      Spike delivers in Canada 400 million does
      👍️0
      make it happen make it happen 4 years ago
      http://archive.fast-edgar.com/20210812/A2Z2M22C3Z2232K222JN2CZ272FUV22SE232/ another company that directs them selling out potentially seems like a big negative along with many downgrades over $20.00 less than current PPS
      👍️0
      Smknf250 Smknf250 4 years ago
      I don’t see any filing that reflects that. Where do you see it?
      👍️0
      make it happen make it happen 4 years ago
      Director sold 725,000 shares @ $55.44 and 25,000 @ $45.83 total of 800,000 shares

      Capitalization at it's finest, run for the hills. imho

      bounce off 30's then into 20's
      👍️0
      make it happen make it happen 4 years ago
      B. Wriley Price target $27.00. Price Per Share PPS is $47.00. Only $20.00 to drop to hit raised price target.
      👍️0
      make it happen make it happen 4 years ago
      $1.40* opps

      1-7 R/S

      Sold drug in a few years will prob do another one sadly
      👍️0
      make it happen make it happen 4 years ago
      Don't forget was like $1.10 at one point. Only 2 mil Revenue VS 2.7 expected.. while losing 56.4 mil in the second quarter or over 225,000,000 million loss for the year.

      -$225,000,000 vs maybe 4 mil on a good year

      Downgraded to under preform

      Sold the drug now have nada

      Also had nice size R/S in the past
      👍️0
      make it happen make it happen 4 years ago
      Posted Revenue of $2 million vs estimated 2.7 mil.

      Loss of $56.4 million second quarter only.

      Huge differences

      Sold the drug... No mo

      Down graded to underperform
      👍️0
      make it happen make it happen 4 years ago
      Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

      Oh no...
      👍️0
      dinogreeves dinogreeves 4 years ago
      ARCT the next NVAX.
      👍️0
      Cosa Cosa 4 years ago
      might be getting squeezed, the float is so low.
      👍️0
      Cosa Cosa 4 years ago
      wow this is pumping
      👍️0
      Atown62 Atown62 4 years ago
      Thoughts now?
      👍️0
      Clemdane Clemdane 4 years ago
      Still long here. This is a looong term buy. Disappointing that we got that massive haircut, but we've had them before and recovered. It's the nature of this volatile sector.
      👍️0
      Atown62 Atown62 4 years ago
      Well?
      👍️0
      lecorb lecorb 4 years ago
      In TDAmeritrade. TIPRANKS 7 SCROE PT: $88.25
      Analyst Ratings, Moderate Buy! Last actualitation!
      Based on the 10 sell-sidetooltipClick this button to read the definition of sell-side analysts who offered a 12-month price target in the last three months. Analysts predict a(n) 122.80% increase from today.
      Kumaraguru Raja
      Brookline Capital Markets
      5Stars target $102.00rankingBuyanalystAction
      Maintained date 2 days ago
      analyst
      Steven Seedhouse
      Raymond James
      5 Stars target ranking Hold analystAction Downgraded date 2 days ago
      analyst
      Yasmeen Rahimi
      Piper Sandler
      5Star target $140.00 ranking Buy analystAction Maintained
      date 2 days ago
      analyst
      Seamus Fernandez
      Guggenheim
      5 Stars target -- ranking Buy analystAction Maintained date
      2 days ago
      Madhu Kumar
      Robert W. Baird
      5 Stars target $69.00 ranking Hold analystAction Downgraded
      date
      2 days ago
      analyst
      Elemer Piros
      Roth Capital
      5 Stars target $77.00 ranking Sell analystAction Maintained
      date 2 days ago
      Mayank Mamtani
      B.Riley Financial
      5 Stars target $138.00 ranking Buy analystAction Maintained
      date 2 days ago
      analyst
      Yigal Nochomovitz
      Citigroup
      5Stars target $133.00 ranking Buy analystAction Maintained
      date 17 days ago
      👍️0
      sanderburwil sanderburwil 4 years ago
      Nope- was just a good “tax dump day” excuse today. Not holding- but really tempted- can only see upwards from here. Cathy woods didn’t sell a share today. Tells you something..
      👍️0
      Willymon Willymon 4 years ago
      ARCT - Re-enter in the 30's. 34-37 seems to be my gate with this one.


      The ol' "buy the rumor, sell the news" strikes again.


      Or, today is last day to sell for 2020 taxes -- Dump day.


      Take your pick.


      It's a pandemic market and more crazy and unexpected things to come.


      Remember, ARCT has a lot more to offer than just COVID solutions.


      Their tech enables many other biotech companies delivery and replication methods.


      ARCT has established a 52-wk high of $130.


      Many think it will go past that.

      👍️0
      ClayTrader ClayTrader 4 years ago
      * * $ARCT Video Chart 12-29-2020 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      Clemdane Clemdane 4 years ago
      Wish I had flipped it. Hindsight is 20/20.
      👍️0
      Willymon Willymon 4 years ago
      ARCT - Me as well. Been in-n-out four times with profits every time.


      When I talk to others they never heard of ARCT.


      Ready for the next leg.
      👍️0
      Clemdane Clemdane 4 years ago
      I'm still in - going to see where the ride takes me
      👍️0
      Willymon Willymon 4 years ago
      ARCT - Still going but nobody on iHub seems aware.


      Some on Stocktwits saying this is going to $500-700.


      I get 10x plays often, but this is a big 10x for sure.
      👍️0
      whytestocks whytestocks 4 years ago
      JUST IN: $ARCT Why Arcturus Therapeutics Stock Soared Today

      Shares of Arcturus Therapeutics Holdings (NASDAQ: ARCT) were soaring 12.7% higher as of 3:28 p.m. EST on Tuesday. The big jump came after the clinical-stage biotech provided its third-quarter update following the market close on Monday. Investors were less interested in Arcturus' fi...

      In case you are interested ARCT - Why Arcturus Therapeutics Stock Soared Today
      👍️0
      whytestocks whytestocks 4 years ago
      Breaking News: $ARCT Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency

      LUNAR® lipids undetectable in plasma 48 hours following drug administration ARCT-810 well tolerated at doses up to 0.3 mg/kg, 0.4 mg/kg cohort to be completed in Q4 Initial dosing of OTC-deficient patients at a U.S. clinical site expected in Q4 Arcturus ...

      Find out more ARCT - Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
      👍️0
      Clemdane Clemdane 5 years ago
      I'm more amazed that anyone posted on this board. But I agree on the breakout!
      👍️0
      Willymon Willymon 5 years ago
      ARCT - In it to win it.
      👍️0
      Biggiee Biggiee 5 years ago
      Breakout! Blue skies.
      👍️0
      Clemdane Clemdane 5 years ago
      Wow! Someone posted on the ARCT board. Thank you very much. I like your chart. I will put my faith in Fibonacci!
      👍️0
      TFMG TFMG 5 years ago
      $ARCT | #ArcturusTherapeutics Breakout Alert



      Potential long above $63.00
      Upside Fibonacci target zone $76.00


      👍️0
      Clemdane Clemdane 5 years ago
      Hello silent ARCT board. Just a message to say I am still here! Still long ARCT.
      👍️0
      Clemdane Clemdane 5 years ago
      That's what I thought. Thank you.
      👍️0
      Willymon Willymon 5 years ago
      $ARCT - Doesn't look like the two are comparable.

      $ARCT's self replicating delivery method along with the protein they are developing to block the keyholes in the host (humans) the spikes on viruses need to infect the host is a unique approach. Can't spike into a receiving host keyhole, no infection or replication. Game over.

      $ARCT would be one shot as a cure for nearly all viruses, including the common flu.

      I'm also a little weary with all these biotechs promising cures so soon.

      Rhinovirus(Flu/common cold) still has no vaccine which they have been working to cure since the 1950's.

      $ARCT thinks they have the total solution.

      👍️0
      Clemdane Clemdane 5 years ago
      Hey do you know anywhere with a good competitive analysis of ARCT vs. the Oxford University vaccine?
      👍️0
      Clemdane Clemdane 5 years ago
      It's truly incredible. I'm thrilled to be here.
      👍️0
      Willymon Willymon 5 years ago
      $ARCT - News out today. How you feeling about those 13's now?
      👍️0
      pix pix 5 years ago
      Shortly they hopefully will give some details to preclinical studies...
      If positive, watch out...
      👍️0
      Willymon Willymon 5 years ago
      $ARCT - Singapore has set and is setting the example to follow in all this.

      The fact that they selected $ARCT to develop a cure is very telling.

      Arcturus announced that it is partnering with Duke-NUS, a partnership between the Duke University School of Medicine and the National University of Singapore, to develop a COVID-19 vaccine to prevent infection by the coronavirus. The government of Singapore will pay for the vaccine's development -- $10 million to be paid part up-front, part upon achievement of unspecified "development milestones." And Singapore will get first dibs on any vaccines produced (plus potential royalties on vaccine sales outside of Singapore).Link>

      👍️0
      pix pix 5 years ago
      If approved in Singapore, they will get access to many Asian countries....
      👍️0
      Clemdane Clemdane 5 years ago
      Incredible. I have it in an IRA. Going to try to get more.
      👍️0
      Willymon Willymon 5 years ago
      $ARCT - $13.90 is sooner. Nobody here is even aware of them. And, with only 1100 on stocktwits, nobody there is aware.

      If you buy at $50 and it goes to $110, you're still in profit. But, now we're into the "What IF" game. Have to be long on $ARCT.

      If they come up with the Covid-19 vaccine, then that also means they also cured thousands of other viruses.

      Their method is to provide humans with a way to clog the keyholes that the spikes on viruses need to plug into to infect and replicate.

      They don't patent some of their methods on purpose because a patent must show exactly how something works. This is to their advantage so other biotech companies have to go figure it out on their own. Trade secret.

      👍️0

      Your Recent History

      NASDAQ
      ARCT
      Arcturus Therapeutics
      BIT
      F13701
      Vontobel Financial Produ...
      BIT
      UB82DG
      Unicredit Bank
      BIT
      P1EM36
      BNP Paribas Issuance
      BIT
      UC1MX1
      Unicredit Bank
      BIT
      UC3UQ0
      Unicredit Bank
      BIT
      NSCIT00A3LV7
      European Investment Bank
      BIT
      UI316A
      Unicredit Bank
      BIT
      UC4YA8
      Unicredit Bank
      BIT
      UB60TG
      Unicredit Bank
      BIT
      UC4677
      Unicredit Bank
      BIT
      F23307
      Vontobel Financial Produ...
      BIT
      UB87QF
      Unicredit Bank
      BIT
      F35509
      Vontobel Financial Produ...
      BIT
      UC16ZR
      Unicredit Bank
      BIT
      UB59MT
      Unicredit Bank
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads